Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial

BACKGROUND: Patients with rare cancers represent 55% of all gynecological malignancies and have poor survival outcomes due to limited treatment options. Combination immunotherapy with the anti-programmed cell death protein 1 (anti-PD-1) antibody nivolumab and the anti-cytotoxic T-lymphocyte-associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Oliver, Kee, Damien, Gao, Bo, Markman, Ben, da Gama Duarte, Jessica, Quigley, Luke, Jackett, Louise, Linklater, Richelle, Strickland, Andrew, Scott, Clare, Mileshkin, Linda, Palmer, Jodie, Carlino, Matteo, Behren, Andreas, Cebon, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593709/
https://www.ncbi.nlm.nih.gov/pubmed/34782426
http://dx.doi.org/10.1136/jitc-2021-003156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593709/
https://www.ncbi.nlm.nih.gov/pubmed/34782426
http://dx.doi.org/10.1136/jitc-2021-003156

Ejemplares similares